Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway

Key Points

• Inhibition of the tpl2/mek2/erk2 pathway represents a critical mechanism of cancer progression.
• Baicalein significantly suppresses this pathway, promoting potential therapeutic applications in thyroid cancer treatment.
• This analysis suggests baicalein could be a promising option for managing papillary thyroid carcinoma (PTC).
• Further exploration is needed to validate these findings and determine clinical efficacy for thyroid cancer patients.